We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 28 september 2018

Latest content from npj Vaccines: 27 September 2018

If you are unable to see the message below, click here to view.
npj Vaccines

Table of Contents: September 2018

Article | 26 September 2018

A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen

Neal Van Hoeven, Steven Wiley, Emily Gage, Andrew Fiore-Gartland, Brian Granger et al.

npj Vaccines 3 , Article number: 39 |  doi: 10.1038/s41541-018-0077-1

Author Correction | 24 September 2018

Author Correction: Selection and evaluation of an efficient method for the recovery of viral nucleic acids from complex biologicals

Sarmitha Sathiamoorthy, Rebecca J. Malott, Lucy Gisonni-Lex & Siemon H. S. Ng

npj Vaccines 3 , Article number: 47 |  doi: 10.1038/s41541-018-0085-1

Review Article | 20 September 2018

A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection

Cody S. Nelson, Betsy C. Herold & Sallie R. Permar

npj Vaccines 3 , Article number: 38 |  doi: 10.1038/s41541-018-0074-4

Article | 17 September 2018

Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making

Sophie J. Rhodes, Jeremie Guedj, Helen A. Fletcher, Thomas Lindenstrøm, Thomas J. Scriba et al.

npj Vaccines 3 , Article number: 36 |  doi: 10.1038/s41541-018-0075-3

Article | 11 September 2018

An Ad/MVA vectored Theileria parva antigen induces schizont-specific CD8+ central memory T cells and confers partial protection against a lethal challenge

Nicholas Svitek, Rosemary Saya, Elias Awino, Stephen Munyao, Robert Muriuki et al.

npj Vaccines 3 , Article number: 35 |  doi: 10.1038/s41541-018-0073-5

Publisher Correction | 11 September 2018

Publisher Correction: Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years

Mai-Chi Trieu, Fan Zhou, Sarah Larteley Lartey, Saranya Sridhar, Siri Mjaaland et al.

npj Vaccines 3 , Article number: 45 |  doi: 10.1038/s41541-018-0081-5

Article | 04 September 2018

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

Rhea N. Coler, Tracey A. Day, Ruth Ellis, Franco M. Piazza, Anna Marie Beckmann et al.

npj Vaccines 3 , Article number: 34 |  doi: 10.1038/s41541-018-0057-5

Your email address is in the npj Vaccines mailing list.
You have been sent this alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: myaccount (You will need to log in to be recognised as a nature.com registrant)
For further technical assistance, please contact our registration department
For print subscription enquiries, please contact our subscription department
For other enquiries, please contact our customer feedback department
Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA
Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.
Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.
Springer Nature